Explore › Finding
Finding adverse
Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although all episodes were subclinical and resolved with dose reduction or expectant management.
Effect size10/20 patients (50%) developed transient BK viremia
Follow-up1 year
ComparatorHistorical rates of BK viremia in kidney transplant recipients on standard CNI-based regimens
Effect summaryadverse; 10/20 patients (50%) developed transient BK viremia
Adverse eventstransient BK viremia 50%, 10 patients

Connected entities

Interventions
alemtuzumab induction immunosuppressive regimen
Conditions
BK polyomavirus
Outcomes
Transient BK viremia

Source

PMC4642731
Renal Transplantation Using Belatacept Without Maintenance Steroids or Calcineurin Inhibitors
Read on PMC → · View in graph →